公司資料
Trevi Therapeutics 股價、新聞與催化劑
- 股票代碼:
- TRVI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
18.08 USD (+0.67%)
收盤價
最後更新: 2026年8月24日
1.92B USD
市值
股價為何變動
As of Aug 24, 2026, TRVI closed up 0.67% at $18.08. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Trevi Therapeutics is a neuroscience and cough-related company focused on chronic cough and severe pruritus biology. Its programs aim to address symptom burdens with targeted therapies.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Trevi sits in specialty biotechnology.
商業模式特徵
The company depends on clinical validation, symptom-specific differentiation, and the ability to build a focused CNS/respiratory story.
生技產業定位
Trevi is a high-catalyst specialty name where clinical data can quickly reshape the investment case.
未來催化劑
- Trevi’s catalysts are Haduvio and the chronic-cough / pruritus opportunities, with the next clinical step deciding whether the asset can become a real franchise. The stock is still driven by proof that the mechanism works in patients.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。